Watson Laboratories receives FDA approval for two generic formulations
Rebecca Aris
pharmaphorum
Watson Laboratories, a subsidiary of Watson Pharmaceuticals, has received FDA approval for two generic drugs.
It received approval of its abbreviated new drug application (ANDA) for trospium chloride extended-release capsules, the generic equivalent to Allergan's Sanctura XR, which is indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency and urinary frequency.
In addition, on Friday, Watson gained FDA approval for the generic version of Sanofi’s Avapro, the brand name for Irbesartan. Avapro is used for high blood pressure and for kidney illness caused by diabetes.
Over the past twelve months Watson has generated revenue of $5.51 billion.
 ,
Related news:
Watson gets FDA approval for generic Sanctura XR and Avapro (The Pharma Letter)
FDA approves Watson Laboratories' generic Sanctura ANDA (Pharmaceutical Business Review)
 ,
